Immunology of inflammatory bowel disease: summary of the proceedings of the Subcommittee on Immunosuppressive Use in IBD.

Journal Article

As outlined, scanty data exist with regard to immunologic therapy in children with IBD despite the fact that the pediatric population affords a unique opportunity for clinical evaluation. Children are less affected by modifying conditions such as smoking, alcohol ingestion, and the long-term use of medications, and because of their specific needs for ponderal and linear growth, children might benefit most from immunological therapy that has been proven to be steroid sparing. Therefore, clinical trials to evaluate the efficacy of 6-MP and/or azathioprine in growing children with Crohn's disease would appear to provide a fruitful avenue for collaborative research. Efforts to organize a multicenter evaluation of these agents have been initiated. The studies are crucial in evaluating the efficacy and safety of immunosuppressive therapy in the pediatric population with IBD.

Full Text

Duke Authors

Cited Authors

  • Markowitz, J; Daum, F; Cohen, SA; Glassman, M; Holmes, RD; Piccoli, D; Rossi, TM; Treem, WR; Ulshen, MH; Winter, HS

Published Date

  • May 1991

Published In

Volume / Issue

  • 12 / 4

Start / End Page

  • 411 - 423

PubMed ID

  • 1678006

International Standard Serial Number (ISSN)

  • 0277-2116


  • eng

Conference Location

  • United States